7th Annual Platelet Colloquium
January 19-21, 2012
Willard InterContinental Hotel
Washington, DC

Attendance by invitation only.  

Overarching Themes:
The overarching theme for the 7th Platelet Colloquium is the translation of fundamental platelet biology and platelet antagonist pharmacology to safe and effective patient care. To this end, platelet biology and imaging will provide the platform for scholarly discussions devoted to trans-catheter cardiac procedures, clinical trials and early safety profiling in drug development.

Objectives

Objective 1: Discuss the evolving field of platelet epigenetics, regulation and imaging as pivotal areas for understanding and translating platelet biology.
Objective 2: Discuss the emerging practice of trans-catheter cardiac procedures and the contributing role of platelets to their success and complications.
Objective 3: Highlight recent phase 2 and 3 clinical trials of platelet antagonists and discuss future strategies for employing molecular technologies toward safety profiling in early drug development

Agenda

 Download Agenda 2012 (37.69 kB)

Thursday, January 19, 2012
7:00 – 9:00 pm Evening Reception and Dinner
 

Friday, January 20, 2012
7:00 – 7:45 am Breakfast

7:45 – 8:00 am Introduction
Harold Dauerman, MD
University of Vermont

Session I: Molecular Biology, Platelet Regulation and Imaging
8:00 – 8:20 am The Role of MicroRNAs in Vascular Remodeling
Eric Small, PhD
University of Rochester Department of Medicine

8:20 – 8:35 am Discussion

8:35 – 8:55 am Platelet-Directed Oligonucleotides
Bruce A. Sullenger, PhD
Duke University Medical Center

8:55 – 9:10 am Discussion

9:10 – 9:30 am Optical Coherence Tomography
Marco Costa, MD, PhD
Case Western Reserve University

9:30 – 9:45 am Discussion

9:45 – 10:10 am Break

Session II: Platelet Biology and Transcatheter Aortic Valve Procedures
10:10 – 10:30 am Emerging Data on Trans-catheter Aortic Valve Replacement
Mauricio G. Cohen, MD
University of Miami Miller School of Medicine

10:30 – 10:45 am Discussion

10:45 – 11:05 am Peri Procedural TAVI Bleeding Complications: Mechanical and Pharmacologic Approaches
Jeffrey J. Popma, MD
Harvard Clinical Research Institute

11:05 – 11:20 am Discussion

11:20 – 11:40 am Peri-procedural TAVI Stroke: Mechanical and Pharmacologic Approaches
Josep Rodes-Cabau, MD
Quebec Heart and Lung Institute at Laval University

11:40 – 11:55 am Discussion

11:55 am – 12:15 pm General Discussion

12:15 – 1:30 pm Lunch and Break

12:15 – 1:30 pm Lunch and Break Buchanan Room
Lower Level

Session III: Clinical Trials of Platelet-Directed Therapy
1:30 – 1:50 pm TRA-CER and LANCELOT
Michelle L. O’Donoghue, MD
Brigham and Women’s Hospital

1:50 – 2:05 pm Discussion

2:05 – 2:25 pm TRILOGY and PEGASUS
E. Magnus Ohman, MD
Duke University Medical Center

2:25 – 2:40 pm Discussion

POSITION DEBATE
2:40 – 3:00 pm New Targets Are Needed in Platelet-directed Therapy
Jessica L. Mega, MD, MPH
Harvard Medical School

3:00 – 3:20 pm New Targets Are Not the Answer (Just Better Drugs and Delivery Systems)
C. Michael Gibson, MD, MS
Harvard Medical School

3:20 – 3:45 pm Discussion

3:45 – 4:00 pm Break
Session IV: Early Career Investigators

4:00 – 4:10 pm Early Career Investigator 1 Presentation
Name
Affiliation

4:10 – 4:20 pm Discussion

4:20 – 4:30 pm Early Career Investigator 2 Presentation
Name
Affiliation

4:30 – 4:40 pm Discussion

4:40 – 4:50 pm Funding, Collaboration and Medical Society Opportunities for Early Career Investigators
Susan S. Smyth, MD, PhD
University of Kentucky

4:30 – 4:40 pm Discussion

5:00 pm Break for Day

6:30 – 9:00 pm Reception and Dinner

Saturday, January 21, 2012
7:00 – 8:00 am Breakfast

Session V: Early Safety Signals in Drug and Device Development
8:00 – 8:25 am Phase O (Micro-dosing) Studies
Richard C. Becker, MD
Duke University Medical Center

8:25 – 8:40 am Discussion

8:40 – 9:05 am Deep Sequencing to Probe Drug Toxicity
Svati H. Shah, MD, MHS
Duke University Medical Center
.
9:05 – 9:20 am Discussion

9:20 – 9:50 am New FDA Regulations to Improve Safety Reporting
Andrew Farb, MD
Food and Drug Administration

9:50 – 10:10 am Discussion

10:10 – 10:50 am Future Research Directions: Moving the Field Forward Group

10:50 – 11:00 am Summary and Closing Remarks
Harold L. Dauerman, MD
University of Vermont

11:00 am Departures

 Download Agenda 2012 (37.69 kB)